You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

CLINICAL TRIALS PROFILE FOR MELPHALAN FLUFENAMIDE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Melphalan Flufenamide Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01897714 ↗ Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients Terminated Oncopeptides AB Phase 1/Phase 2 2013-07-01 The study will explore escalating doses of melflufen in combination with dexamethasone in small groups of patients to find the maximum tolerated dose of melflufen. That dose will then be used to determine the efficacy and safety profile of melflufen in combination with dexamethasone in a larger group of patients.
NCT02963493 ↗ A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients Active, not recruiting Precision For Medicine Phase 2 2016-12-28 This study will evaluate melflufen in combination with dexamethasone in the treatment of relapsed refractory multiple myeloma in adult patients with disease refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. All patients in the study will be treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day cycle.
NCT02963493 ↗ A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients Active, not recruiting Precision Oncology Phase 2 2016-12-28 This study will evaluate melflufen in combination with dexamethasone in the treatment of relapsed refractory multiple myeloma in adult patients with disease refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. All patients in the study will be treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day cycle.
NCT02963493 ↗ A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients Active, not recruiting Oncopeptides AB Phase 2 2016-12-28 This study will evaluate melflufen in combination with dexamethasone in the treatment of relapsed refractory multiple myeloma in adult patients with disease refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. All patients in the study will be treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day cycle.
NCT03151811 ↗ A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide Active, not recruiting Oncopeptides AB Phase 3 2017-06-12 This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients with RRMM following 2-4 lines of prior therapy and who are refractory to lenalidomide in the last line of therapy as demonstrated by disease progression on or within 60 days of completion of the last dose of lenalidomide. Patients will receive either melflufen+dex or pomalidomide+dex.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Melphalan Flufenamide Hydrochloride

Condition Name

Condition Name for Melphalan Flufenamide Hydrochloride
Intervention Trials
Multiple Myeloma 4
RRMM 2
AL Amyloidosis 1
Relapse Multiple Myeloma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Melphalan Flufenamide Hydrochloride
Intervention Trials
Neoplasms, Plasma Cell 5
Multiple Myeloma 5
Immunoglobulin Light-chain Amyloidosis 1
Amyloidosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Melphalan Flufenamide Hydrochloride

Trials by Country

Trials by Country for Melphalan Flufenamide Hydrochloride
Location Trials
United States 37
Czechia 6
Spain 5
Poland 5
France 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Melphalan Flufenamide Hydrochloride
Location Trials
Massachusetts 5
California 4
Ohio 4
New York 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Melphalan Flufenamide Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Melphalan Flufenamide Hydrochloride
Clinical Trial Phase Trials
Phase 3 2
Phase 2 3
Phase 1/Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Melphalan Flufenamide Hydrochloride
Clinical Trial Phase Trials
Active, not recruiting 7
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Melphalan Flufenamide Hydrochloride

Sponsor Name

Sponsor Name for Melphalan Flufenamide Hydrochloride
Sponsor Trials
Oncopeptides AB 8
Precision For Medicine 1
Precision Oncology 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Melphalan Flufenamide Hydrochloride
Sponsor Trials
Industry 10
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.